Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Zarnestra Receives “Not Approvable” Letter From FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Oral leukemia agent is not approvable based on Phase II clinical trials, the agency said. J&J maintains it is committed to developing tipifarnib and will determine “appropriate next steps.”

You may also be interested in...



Kura May Have Found A Place For Tipifarnib In Head-And-Neck Cancer

The repurposed drug showed substantial improvement over existing therapies in second-line treatment of patients with HRAS-mutant tumors.

Johnson & Johnson On Track For Eight NME Filings, Approvals In 2007

Firm plans to submit a follow-on to the recently approved antipsychotic Invega by year-end.

Johnson & Johnson On Track For Eight NME Filings, Approvals In 2007

Firm plans to submit a follow-on to the recently approved antipsychotic Invega by year-end.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS062486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel